Search research articles
Contact Us
Filters
Showing results (51-60 of 64) with videos related to
Page
of 7
Sort By:
British Journal of Clinical Pharmacology
|
May 19, 2022
The role of placebo response in the efficacy outcome assessment in viloxazine extended-release pivotal trials in paediatric subjects with attention-deficit/hyperactivity disorder
Azmi Nasser, Roberto Gomeni, Zhao Wang, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
|
April 21, 2020
Risk of target non-attainment in obese compared to non-obese patients in calculated linezolid therapy
L Ehmann, P Simon, D Busse, et al.
Cancer Chemotherapy and Pharmacology
|
January 29, 1999
Fractionated administration of high-dose cyclophosphamide: influence on dose-dependent changes in pharmacokinetics and metabolism
D Busse, F W Busch, E Schweizer, et al.
Psychiatry Research
|
November 14, 2022
Predicting efficacy of viloxazine extended-release treatment in adults with ADHD using an early change in ADHD symptoms: Machine learning Post Hoc analysis of a phase 3 clinical trial
Stephen V Faraone, Roberto Gomeni, Joseph T Hull, et al.
The Journal of Biological Chemistry
|
March 4, 2000
Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity
D Busse, R S Doughty, T T Ramsey, et al.
International Journal of Clinical Practice
|
May 10, 2021
Evaluating the likelihood to be helped or harmed after treatment with viloxazine extended-release in children and adolescents with attention-deficit/hyperactivity disorder
Azmi Nasser, Alisa R Kosheleff, Joseph T Hull, et al.
Journal of Child and Adolescent Psychopharmacology
|
February 18, 2021
Translating Attention-Deficit/Hyperactivity Disorder Rating Scale-5 and Weiss Functional Impairment Rating Scale-Parent Effectiveness Scores into Clinical Global Impressions Clinical Significance Levels in Four Randomized Clinical Trials of SPN-812 (Viloxazine Extended-Release) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder
Azmi Nasser, Alisa R Kosheleff, Joseph T Hull, et al.
Antimicrobial Agents and Chemotherapy
|
May 23, 2022
High-Dosage Fosfomycin Results in Adequate Plasma and Target-Site Exposure in Morbidly Obese and Nonobese Nonhyperfiltration Patients
D Busse, P Simon, D Petroff, et al.
Clinical Therapeutics
|
March 22, 2021
Once-Daily SPN-812 200 and 400 mg in the treatment of ADHD in School-aged Children: A Phase III Randomized, Controlled Trial
Azmi Nasser, Tesfaye Liranso, Toyin Adewole, et al.
Psychopharmacology Bulletin
|
June 7, 2021
A Phase 3 Placebo-Controlled Trial of Once-Daily 400-mg and 600-mg SPN-812 (Viloxazine Extended-Release) in Adolescents with ADHD
Azmi Nasser, Tesfaye Liranso, Toyin Adewole, et al.
Page
of 7
Search research articles
Search
Showing results (51-60 of 64) with videos related to
Sort By:
Page
of 7
British Journal of Clinical Pharmacology
|
May 19, 2022
The role of placebo response in the efficacy outcome assessment in viloxazine extended-release pivotal trials in paediatric subjects with attention-deficit/hyperactivity disorder
Azmi Nasser, Roberto Gomeni, Zhao Wang, et al.
Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases
|
April 21, 2020
Risk of target non-attainment in obese compared to non-obese patients in calculated linezolid therapy
L Ehmann, P Simon, D Busse, et al.
Cancer Chemotherapy and Pharmacology
|
January 29, 1999
Fractionated administration of high-dose cyclophosphamide: influence on dose-dependent changes in pharmacokinetics and metabolism
D Busse, F W Busch, E Schweizer, et al.
Psychiatry Research
|
November 14, 2022
Predicting efficacy of viloxazine extended-release treatment in adults with ADHD using an early change in ADHD symptoms: Machine learning Post Hoc analysis of a phase 3 clinical trial
Stephen V Faraone, Roberto Gomeni, Joseph T Hull, et al.
The Journal of Biological Chemistry
|
March 4, 2000
Reversible G(1) arrest induced by inhibition of the epidermal growth factor receptor tyrosine kinase requires up-regulation of p27(KIP1) independent of MAPK activity
D Busse, R S Doughty, T T Ramsey, et al.
International Journal of Clinical Practice
|
May 10, 2021
Evaluating the likelihood to be helped or harmed after treatment with viloxazine extended-release in children and adolescents with attention-deficit/hyperactivity disorder
Azmi Nasser, Alisa R Kosheleff, Joseph T Hull, et al.
Journal of Child and Adolescent Psychopharmacology
|
February 18, 2021
Translating Attention-Deficit/Hyperactivity Disorder Rating Scale-5 and Weiss Functional Impairment Rating Scale-Parent Effectiveness Scores into Clinical Global Impressions Clinical Significance Levels in Four Randomized Clinical Trials of SPN-812 (Viloxazine Extended-Release) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder
Azmi Nasser, Alisa R Kosheleff, Joseph T Hull, et al.
Antimicrobial Agents and Chemotherapy
|
May 23, 2022
High-Dosage Fosfomycin Results in Adequate Plasma and Target-Site Exposure in Morbidly Obese and Nonobese Nonhyperfiltration Patients
D Busse, P Simon, D Petroff, et al.
Clinical Therapeutics
|
March 22, 2021
Once-Daily SPN-812 200 and 400 mg in the treatment of ADHD in School-aged Children: A Phase III Randomized, Controlled Trial
Azmi Nasser, Tesfaye Liranso, Toyin Adewole, et al.
Psychopharmacology Bulletin
|
June 7, 2021
A Phase 3 Placebo-Controlled Trial of Once-Daily 400-mg and 600-mg SPN-812 (Viloxazine Extended-Release) in Adolescents with ADHD
Azmi Nasser, Tesfaye Liranso, Toyin Adewole, et al.
Page
of 7